Avalyn to Present on AP01 and Novel Inhaled Therapies at 2024 ATS Conference

Avalyn Pharma Inc., a biopharmaceutical company specializing in inhaled therapies for severe lung diseases, has announced its participation in the 2024 American Thoracic Society (ATS) International Conference, scheduled from May 17-22, 2024, in San Diego, CA. The company will present new findings related to AP01, an innovative inhaled formulation of pirfenidone aimed at treating progressive pulmonary fibrosis.

Avalyn's primary focus during the conference will be on presenting the long-term safety and efficacy data from the ATLAS trial's open-label extension study. This data will provide critical insights into the performance of AP01 in patients with pulmonary fibrosis, a life-threatening condition characterized by lung scarring and diminished lung function.

CEO Lyn Baranowski expressed enthusiasm about the opportunity to share these significant results, emphasizing the potential of AP01 to offer a safer and more effective treatment option for pulmonary fibrosis patients. Baranowski highlighted that the data underscores Avalyn's commitment to developing transformative inhaled therapies, reflecting the collective effort of the company's team and its medical collaborators.

The company's presentations at the ATS conference are comprehensive and span multiple formats. Avalyn's event schedule includes participation in the ATS Industry Theater program, where the company will discuss its Phase 2b trial of AP01. Avalyn's leadership will also engage in a poster presentation and moderate a panel during the Respiratory Innovation Summit, an event that brings together stakeholders from various sectors to promote advancements in respiratory medicine.

Key presentations at the ATS conference include:

1. Poster Presentation: Avalyn will showcase a poster on targeted inhaled therapies for rare respiratory diseases. Dr. Allison Trucillo, Vice President of Medical Affairs, will present this data starting May 17, 2024, at the Manchester Grand Hyatt San Diego.

2. Panel Discussion: Dr. Craig S. Conoscenti, Senior Vice President of Clinical Development, will moderate a panel on pulmonary function tests on May 18, 2024, at the Manchester Grand Hyatt San Diego.

3. Poster Sessions: On May 20, 2024, Avalyn will deliver three poster sessions at the San Diego Convention Center, highlighting different aspects of the ATLAS study:
- Safety and efficacy data of inhaled pirfenidone (AP01)
- Post-hoc analysis showing reduced risk of disease progression with AP01
- Analysis of e-lung biomarker scores between treatment groups

4. Industry Theater Conference Event: Dr. Howard Lazarus and Dr. Steven Nathan will present on inhaled pirfenidone for treating progressive pulmonary fibrosis on May 20, 2024, at the San Diego Convention Center.

5. Scientific Symposium: Dr. Craig S. Conoscenti will discuss designing clinical trials with diversity and inclusion in mind during a symposium on May 20, 2024, at the Marriott Marquis San Diego Marina.

Avalyn Pharma is dedicated to creating inhaled treatments tailored to rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILD). Pulmonary fibrosis leads to significant lung function decline, reduced quality of life, and increased mortality. Current therapies can slow the disease's progression but are often accompanied by severe side effects that limit their practicality.

Avalyn's innovative approach focuses on developing inhaled formulations of approved medications to minimize systemic exposure and deliver drugs directly to the lungs. The company's flagship product, AP01, has shown promising results in clinical trials, involving 150 patients with various forms of pulmonary fibrosis. These trials have demonstrated both improved efficacy and enhanced safety compared to existing therapies.

Avalyn Pharma's participation in the ATS International Conference highlights the company's ongoing efforts to address the critical needs in treating pulmonary fibrosis through advanced inhaled therapies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!